Polyoma Virus Jc Peptides And Proteins In Vaccination And Diagnostic Applications

Abstract

The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.


Claims
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Aug 22, 2017
  • Application: Jul 23, 2012
    US US 201214234065 A
  • Priority: Jul 23, 2012
    EP EP 2012064445 W
  • Priority: Jul 22, 2011
    EP EP 11006031 A

Download Citation


Sign in to the Lens

Feedback